Secukinumab
- SubcutSecukinumabCosentyx
Mechanism of Action
- A human monoclonal antibody directed against IL-17A, a cytokine produced mainly by TH17 cells that activates neutrophils and promotes inflammation.
Clinical Use
- Indications
- Ankylosing spondylitis
- Psoriatic arthritis
- Plaque psoriasis
- Adverse Effects
- Infections (particularly upper respiratory tract infections)
- Oral herpes
- Diarrhoea